Lin Yingying, Wang Xin, Li Yanyan, Cui Xinyu, Zhu Na, Li Xin
Center of Integrative Medicine, Peking University Ditan Teaching Hospital, Beijing, China.
Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Biomol Biomed. 2025 Mar 7;25(4):925-939. doi: 10.17305/bb.2024.11246.
The C6orf120 gene is a novel gene whose function has not been fully defined. Previous studies have associated it with various liver pathologies, but its specific role in hepatocellular carcinoma (LIHC) remains unclear. This study aimed to investigate the diagnostic and prognostic value of C6orf120 in LIHC, as well as its potential biological functions. In this preliminary research, we utilized data from various databases and bioinformatics tools, including TCGA, GEO, TIMER2, HPA, GEPIA, Linkeomics, Metascape, CIBERSORT, TargetScan, DIANA-microT, RNAinter, and ENCORI, to analyze the expression patterns and mechanisms of C6orf120 in LIHC. Our bioinformatics analysis revealed that C6orf120 is upregulated in LIHC and may serve as a diagnostic and prognostic biomarker. The aberrant expression of C6orf120 in LIHC was further supported by clinical samples and cell lines. In vitro experiments demonstrated that the knockdown of C6orf120 in HepG2 cells significantly reduced migration capacity without affecting proliferation. Additionally, the downregulation of C6orf120 in LIHC cells appeared to inhibit endothelial cell migration and angiogenesis, which are critical in tumorigenesis and development. In conclusion, our findings suggest that C6orf120 could serve as a novel diagnostic and prognostic biomarker for LIHC and is expected to be a prognostic marker and a potential therapeutic target in the clinical management of LIHC.
C6orf120基因是一个功能尚未完全明确的新基因。先前的研究已将其与多种肝脏病理状况相关联，但其在肝细胞癌（LIHC）中的具体作用仍不清楚。本研究旨在探讨C6orf120在LIHC中的诊断和预后价值及其潜在的生物学功能。在这项初步研究中，我们利用了来自多个数据库和生物信息学工具的数据，包括TCGA、GEO、TIMER2、HPA、GEPIA、Linkeomics、Metascape、CIBERSORT、TargetScan、DIANA-microT、RNAinter和ENCORI，来分析C6orf120在LIHC中的表达模式和机制。我们的生物信息学分析表明，C6orf120在LIHC中上调，可能作为一种诊断和预后生物标志物。临床样本和细胞系进一步支持了C6orf120在LIHC中的异常表达。体外实验表明，在HepG2细胞中敲低C6orf120可显著降低迁移能力而不影响增殖。此外，LIHC细胞中C6orf120的下调似乎抑制了内皮细胞迁移和血管生成，而这在肿瘤发生和发展中至关重要。总之，我们的研究结果表明，C6orf120可作为LIHC一种新的诊断和预后生物标志物，有望成为LIHC临床管理中的预后标志物和潜在治疗靶点。
